Local Recurrence of Malignant Tumor of Soft TissuePhase 3NCT02120768
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas
A Phase 3 study testing barrier resection/1cm resection in people with Local Recurrence of Malignant Tumor of Soft Tissue, run by Fudan University at 1 site in China.
Trial summary
The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues. Read more about this study
- Who is it for?
- Ages 14 to 80 years
- Conditions the study is for
- Local Recurrence of Malignant Tumor of Soft Tissue
- What is being tested?
- barrier resection/1cm resection
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteChina
- Study dates
- Mar 2014to Dec 2018
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Confirmed recurrent ESTS.
- Confirmed imaging targets, resectable, no metastasis.
- No radiochemotherapy in the past 3 months.
- ECOG status of 0-1.
- Age between 14 and 80.
- WBC over 3000/µL,Neutriphil ≥1,500/µL, PLT ≥100,000/µL.
- Understand the and sign the consent form with compliance.
Who cannot join
- Pregnant or lactating.
- Metastasis.
- Radiotherapy or chemotherapy in the past 3 months.
- Another malignancy in the past 3 years.
- Uncontrollable heart disease or psychologically unstable.
- Severe infection.
Show all 9Show fewer
- In recovery of last operation.
- Preoperative MSTS score less than 15.
- Other dysfunctions or situations which assessed to be unsuitable for the trial.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032
Lingling Pan, 0862164175590, yingqiangshi@126.com
Yong Chen, 0862164175590, chenyongfudan@gmail.com
About this study
Official title: Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas
The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues. This is based on the fact that the goal of local surgical treatment is to remove the tumor with negative margin and best functional outcome, but there is a lack of standard principle of surgery. Some surgical oncologists recommended enlarging surgical field in which case the associated muscle was removed from origin to insertion, the previous surgical scar and radiation field were also grossly remove, though there would be extra trauma and unacceptable function impairment, they believe that patients would benefit from "big operations". Most other surgeons would perform a sarcoma resection through normal tissues, and reported a fair local control as long as a negative margin was obtained. As reported by various authors, recurrent STSs are associated with higher risk to develop further recurrence as compared to primary STSs, thus, efforts should focus on this category of STSs to improve outcome.
Read the detailed description
- Background Soft tissue sarcoma (STS) is a category of malignancy with mesenchymal origin, its incidence is 10-20 cases/million and accounts for 1% of all human malignant neoplasms. The most common STSs include undifferentiated polymorphic sarcoma/malignant fibrohistiocytoma (UPS/MFH), synovial sarcoma, fibrosarcoma and liposarcoma. The rarity of the tumor, the various subtypes and heterogeneous behavior make the diagnosis and treatment of sarcoma a challenge. Many patients, especially those from developing countries were diagnosed with a late stage disease or recurrent sarcoma being treated with many unplanned resections, which would impact limb function or even survival. Except those with unresectable diseases, surgical resection remains the mainstay of treatment for soft tissue sarcoma, the defined aim of surgery is R0 resection with a good functional outcome. With development of modern strategy and technique, limb sparing surgery has been implied in more than 80% of cases and was proven to have similar local control as amputation without sacrifice of survival. The most common limb sparing surgeries include compartment resection and wide resection. Compartment resection has been gradually replaced by functional compartment resection, aiming at more function preservation, while so far there has been no evidence-based and clinically comprehensible definition of the term "wide resection". Many textbooks still advocate the need to obtain a 2- to 3cm surgical margin width in all directions when resecting a soft tissue sarcoma, but some other orthopaedic and surgical oncologists recommended 1cm or 5cm margin width for STS. Local recurrence-free interval is the major end-point in evaluating the quality of surgery, functional outcomes and treatment morbidities are equally important end-points. Five-year local recurrence-free estimations for limb and trunk wall sarcoma should be below 20%, and approaching 10%. Margin status is reported to be a key prognostic factor for local recurrence. Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, and should be co-assessed by surgical oncologist and pathologist. Different margin width of 1-5cm has been recommended for obtaining a safe margin, as stated above, but in a limb sparing surgery, margins exceeding 1 cm were obtained in only 47% of patients and it's nearly impossible to obtain 2 cm margins in all directions for an extremity STS. With adjuvant therapies, a close dissection can be adequate in order to preserve important functional structures, but the following questions are unanswered:1. How close is safe for STS resection? 2. Is a margin close to periosteum has the same oncologic result as a margin close to muscular membrane or subcutaneous fat? As we all know that local anatomy influences sarcoma growth by setting natural barriers to extension, and sarcoma might infiltrate or compress surrounding structures, thus, a rational resection should be designed mainly based on the understanding of these characteristics. Scientists investigated different barriers and converted them into different margin width in order to facilitate a safe resection. Among these efforts, a barrier resection was reported to be an option for recurrent extremity STSs and obtained satisfactory local control. Barrier resection was defined as "en bloc" removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located. Furthermore, a barrier resection can be designed preoperatively based on imaging studies and is easy to perform intraoperatively based on understanding of local anatomy, and also, it's easy for pathologists to obtain materials for margin evaluation. Another content of barrier resection is repair and reconstruction, which includes vessel replacement, dynamic restoration, supporting and wound coverage. With the assistance of repair and reconstruction, sacrifice of margin safety would be no longer needed and in some selected cases, adjuvant radiotherapy would be spared. Well defined "R" classification is widely implied to determine the margin status in STSs, in brief, R0 is microscopically negative, R1 is microscopically positive but macroscopically negative, R2 is macroscopically positive. The goal of resection is R0 resection with a good functional outcome, but it's impossible to confirm margin status for all cut edges intraoperatively, while postoperative examination can't guide intraoperative manipulation. So far there has been no evidence-based and clinically comprehensible definition of the term "wide resection", though many guidelines recommended a 1cm normal tissue around tumor. Thus, our study aims at investigating the difference between barrier resection and 1cm margin resection, with local recurrence as main end-point, disease specific survival and functional outcome as secondary end-points.
- Aims First end-point: Compare the local recurrence between barrier resection and 1cm margin resection.
Secondary end-point:
Disease specific survival (DSS) Functional outcome (MSTS) Surgical complications (Grade)
The first end-point is to compare the local recurrence between barrier resection and 1cm margin resection, it's designed based on the following facts:
- In compartment theory of Enneking, muscle is independent compartment and most recurrent STSs develop in the same compartment as its original site.
- The "R" classification of UICC categorized resection margin with margin status, but not margin width, most guidelines recommended 1cm margin resection and a muscle resection from origin to insertion was not required any more. As a result, local control for recurrent STSs was reported to have higher recurrent rate as compared to primary STSs.
- Some authors in China reported that barrier resection was effective in local control with acceptable extremity functional outcome.
- Schedule:
From Jan. 2014 to Dec. 2018, as following:
2014.01-2014.03: Methodology and infrastructure construction. 2014.04-2015.09: Sample collection, Surveillance, data gathering. 2015.10-2018.12: Followup, data analysis.
Patients with recurrent extremity STSs are candidates of the study, preoperative CT or MRI should be taken for orientation. As reported previously, barrier resection was associated with comparable local recurrent rate as primary STSs, closing to 15% and 5% of amputation rate, while Eilber reported a recurrent rate and amputation rate for recurrent STSs of 18% and 38%, respectively.
Muscles in trunk don't have independent compartment, thus a barrier resection is not feasible for patients with trunk recurrent STSs. Retroperitoneal STSs have distinctive anatomy and biological behavior, thus are also excluded.
- Randomization: Patients would be randomized as 1:1 to two groups. Randomization should be taken after radiological evaluation and inclusion. Patients would be stratified according to histologic subtypes and adjuvant therapies.
Patients would be followed up for at least 24 months for disease status and the survival information will be followed up to postoperative 60 months.
- Being tested
- barrier resection/1cm resection
- Keywords
- Barrier resection, Local recurrence, Complication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
barrier resection/1cm resectionProcedure or surgery
For Arm "Barrier resection", if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm "1cm resection", if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas.
| Study group | Role | What they receive |
|---|---|---|
| Barrier resection | Experimental | Barrier resection was defined as "en bloc" removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs. Receives: Procedure: barrier resection/1cm resection |
| 1 cm resection | Active comparator | Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs. Receives: Procedure: barrier resection/1cm resection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants with local recurrence.
Measured: up to 2 years
Secondary outcomes (1)
percentage of participants with surgical complications
Measured: up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2014 (estimated)
- Study startMar 2014
- Primary completionDec 2015 (estimated)
- Study completionDec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Local Recurrence of Malignant Tumor of Soft TissueStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shi Yingqiang, Fudan University
- Investigators
- Yong Chen, Principal investigator, Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02120768
- Sponsor's protocol ID
- 1310128-1-1312
- Status last verified
- Apr 2014
- First submitted
- 1 Apr 2014
- Last updated
- 23 Apr 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas
- ClinicalTrials.gov ID
- NCT02120768
- Acronym / sponsor ID
- 1310128-1-1312
- Keywords
- Barrier resection, Local recurrence, Complication
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- Mar 2014
- Primary completion
- Dec 2015 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 23 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues. This is based on the fact that the goal of local surgical treatment is to remove the tumor with negative margin and best functional outcome, but there is a lack of standard principle of surgery. Some surgical oncologists recommended enlarging surgical field in which case the associated muscle was removed from origin to insertion, the previous surgical scar and radiation field were also grossly remove, though there would be extra trauma and unacceptable function impairment, they believe that patients would benefit from "big operations". Most other surgeons would perform a sarcoma resection through normal tissues, and reported a fair local control as long as a negative margin was obtained. As reported by various authors, recurrent STSs are associated with higher risk to develop further recurrence as compared to primary STSs, thus, efforts should focus on this category of STSs to improve outcome.
Detailed description
- Background Soft tissue sarcoma (STS) is a category of malignancy with mesenchymal origin, its incidence is 10-20 cases/million and accounts for 1% of all human malignant neoplasms. The most common STSs include undifferentiated polymorphic sarcoma/malignant fibrohistiocytoma (UPS/MFH), synovial sarcoma, fibrosarcoma and liposarcoma. The rarity of the tumor, the various subtypes and heterogeneous behavior make the diagnosis and treatment of sarcoma a challenge. Many patients, especially those from developing countries were diagnosed with a late stage disease or recurrent sarcoma being treated with many unplanned resections, which would impact limb function or even survival. Except those with unresectable diseases, surgical resection remains the mainstay of treatment for soft tissue sarcoma, the defined aim of surgery is R0 resection with a good functional outcome. With development of modern strategy and technique, limb sparing surgery has been implied in more than 80% of cases and was proven to have similar local control as amputation without sacrifice of survival. The most common limb sparing surgeries include compartment resection and wide resection. Compartment resection has been gradually replaced by functional compartment resection, aiming at more function preservation, while so far there has been no evidence-based and clinically comprehensible definition of the term "wide resection". Many textbooks still advocate the need to obtain a 2- to 3cm surgical margin width in all directions when resecting a soft tissue sarcoma, but some other orthopaedic and surgical oncologists recommended 1cm or 5cm margin width for STS. Local recurrence-free interval is the major end-point in evaluating the quality of surgery, functional outcomes and treatment morbidities are equally important end-points. Five-year local recurrence-free estimations for limb and trunk wall sarcoma should be below 20%, and approaching 10%. Margin status is reported to be a key prognostic factor for local recurrence. Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, and should be co-assessed by surgical oncologist and pathologist. Different margin width of 1-5cm has been recommended for obtaining a safe margin, as stated above, but in a limb sparing surgery, margins exceeding 1 cm were obtained in only 47% of patients and it's nearly impossible to obtain 2 cm margins in all directions for an extremity STS. With adjuvant therapies, a close dissection can be adequate in order to preserve important functional structures, but the following questions are unanswered:1. How close is safe for STS resection? 2. Is a margin close to periosteum has the same oncologic result as a margin close to muscular membrane or subcutaneous fat? As we all know that local anatomy influences sarcoma growth by setting natural barriers to extension, and sarcoma might infiltrate or compress surrounding structures, thus, a rational resection should be designed mainly based on the understanding of these characteristics. Scientists investigated different barriers and converted them into different margin width in order to facilitate a safe resection. Among these efforts, a barrier resection was reported to be an option for recurrent extremity STSs and obtained satisfactory local control. Barrier resection was defined as "en bloc" removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located. Furthermore, a barrier resection can be designed preoperatively based on imaging studies and is easy to perform intraoperatively based on understanding of local anatomy, and also, it's easy for pathologists to obtain materials for margin evaluation. Another content of barrier resection is repair and reconstruction, which includes vessel replacement, dynamic restoration, supporting and wound coverage. With the assistance of repair and reconstruction, sacrifice of margin safety would be no longer needed and in some selected cases, adjuvant radiotherapy would be spared. Well defined "R" classification is widely implied to determine the margin status in STSs, in brief, R0 is microscopically negative, R1 is microscopically positive but macroscopically negative, R2 is macroscopically positive. The goal of resection is R0 resection with a good functional outcome, but it's impossible to confirm margin status for all cut edges intraoperatively, while postoperative examination can't guide intraoperative manipulation. So far there has been no evidence-based and clinically comprehensible definition of the term "wide resection", though many guidelines recommended a 1cm normal tissue around tumor. Thus, our study aims at investigating the difference between barrier resection and 1cm margin resection, with local recurrence as main end-point, disease specific survival and functional outcome as secondary end-points.
- Aims First end-point: Compare the local recurrence between barrier resection and 1cm margin resection.
Secondary end-point:
Disease specific survival (DSS) Functional outcome (MSTS) Surgical complications (Grade)
The first end-point is to compare the local recurrence between barrier resection and 1cm margin resection, it's designed based on the following facts:
- In compartment theory of Enneking, muscle is independent compartment and most recurrent STSs develop in the same compartment as its original site.
- The "R" classification of UICC categorized resection margin with margin status, but not margin width, most guidelines recommended 1cm margin resection and a muscle resection from origin to insertion was not required any more. As a result, local control for recurrent STSs was reported to have higher recurrent rate as compared to primary STSs.
- Some authors in China reported that barrier resection was effective in local control with acceptable extremity functional outcome.
- Schedule:
From Jan. 2014 to Dec. 2018, as following:
2014.01-2014.03: Methodology and infrastructure construction. 2014.04-2015.09: Sample collection, Surveillance, data gathering. 2015.10-2018.12: Followup, data analysis.
Patients with recurrent extremity STSs are candidates of the study, preoperative CT or MRI should be taken for orientation. As reported previously, barrier resection was associated with comparable local recurrent rate as primary STSs, closing to 15% and 5% of amputation rate, while Eilber reported a recurrent rate and amputation rate for recurrent STSs of 18% and 38%, respectively.
Muscles in trunk don't have independent compartment, thus a barrier resection is not feasible for patients with trunk recurrent STSs. Retroperitoneal STSs have distinctive anatomy and biological behavior, thus are also excluded.
- Randomization: Patients would be randomized as 1:1 to two groups. Randomization should be taken after radiological evaluation and inclusion. Patients would be stratified according to histologic subtypes and adjuvant therapies.
Patients would be followed up for at least 24 months for disease status and the survival information will be followed up to postoperative 60 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Barrier resection | Experimental | Procedure: barrier resection/1cm resectionBarrier resection was defined as "en bloc" removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs. |
| 1 cm resection | Active comparator | Procedure: barrier resection/1cm resectionSurgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs. |
Who may qualify
- Ages
- 14 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Confirmed recurrent ESTS.
- Confirmed imaging targets, resectable, no metastasis.
- No radiochemotherapy in the past 3 months.
- ECOG status of 0-1.
- Age between 14 and 80.
Key exclusion criteria (9 listed)
- Pregnant or lactating.
- Metastasis.
- Radiotherapy or chemotherapy in the past 3 months.
- Another malignancy in the past 3 years.
- Uncontrollable heart disease or psychologically unstable.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| barrier resection/1cm resectionFor Arm "Barrier resection", if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm "1cm resection", if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas. | Procedure or surgery | 1 cm resection, Barrier resection |
Primary outcome
Percentage of participants with local recurrence.
Time frame: up to 2 years
1 secondary outcome
percentage of participants with surgical complications
Time frame: up to 30 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2014.
Related trials for Local Recurrence of Malignant Tumor of Soft Tissue
RecruitingPhase 3
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Giant Cell Tumor of Bone
RecruitingPhase 1/2
B7-H3 NIR Imaging for Osteosarcoma Surgery
Osteosarcoma, Resection Margins
Not yet recruitingPhase 2
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Recurrent Cancer, Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yong Chen principal investigator
Fudan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing barrier resection/1cm resection in people with Local Recurrence of Malignant Tumor of Soft Tissue, run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants with local recurrence. (time frame: up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2014.